Key Takeaways Nyxoah gains FDA clearance for its Genio system to treat moderate to severe sleep apnea.Genio's design delivers bilateral nerve stimulation without implanted batteries.Trial results showed up to 71% median AHI reduction across all sleeping positions.Nyxoah (NYXH) recently received FDA approval for its Genio system, an innovative therapy for moderate to severe Obstructive Sleep Apnea (OSA). Featuring a leadless, battery-free design powered by an upgradable wearable, Genio offers a unique bilate ...

Nyxoah Announces Preliminary Results for the Second Quarter of 2025 Mont-Saint-Guibert, Belgium – August 11, 2025, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced certain preliminary, unaudited financial results for the second quarter of 2025 and other business updates. Preliminary, Unaudited Second Quarter 2025 Financial Results a ...